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What is already known about the topic?
•• Population-wide studies have shown increasing prevalence rates of using sedative substances to keep a patient in deep 
sedation until death.
•• There is no consensus among healthcare professionals regarding the conceptual definition and procedural understand-
ing of these sedation practices.
•• Empirical studies mostly focus on specialized palliative care settings, but it is known that a large share of continuously 
deeply sedated patients die outside specialized palliative care.
What this paper adds?
•• This study identified certain patient groups that are less likely to receive sedative substances to be kept in deep sedation 
until death when warranted.
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•• Across all care settings, the administration of sedative substances to keep a patient in deep sedation until death appears 
to be done primarily as part of or after intensified alleviation of pain and symptoms.
•• Unmarried nursing home residents and hospital patients aged older than 80 years or diagnosed with cancer are less 
likely to receive sedative substances until death.
Implications for the practice, theory or policy
•• Healthcare professionals should take care to provide sedative substances to all patients when warranted regardless of 
setting, age or diagnosis.
•• Our findings point to the need for improved multidisciplinary collaboration and knowledge transfer to improve early 
identification of patients who could benefit from continuous deep sedation until death.
•• To reach consensus on good clinical end-of-life care, more attention should be given to the management of refractory 
symptoms and the administration of opioids in terminally ill patients across different care settings.
Introduction
The provision of adequate relief of pain is a central aspect of 
medical care at the end of life. International findings reveal 
increasing prescribing rates of pain medication, with, for 
example, a more than twofold increase in prescription rates 
of strong opioids in Switzerland between 2006 and 2013.1 
There is substantial variation in prevalence estimates of pain 
between countries and study population, with trends 
increasing by age.2–4 In end-of-life care, intensified alleviation 
of pain treatments are part of professionals’ everyday clinical 
practice.5 In Switzerland, physicians reported that more than 
three out of five patients dying non-suddenly received medi-
cation to intensively alleviate pain prior to death.6–8
Adequate symptom control is particularly challenging in 
terminally ill patients for whom all alternative treatment 
options have failed.9 Where conventional symptom control 
is not sufficient, the administration of sedative substances 
can be considered.10 According to a patient’s need, the 
depth and duration of sedation vary from mild to deep and 
intermittent to continuously until death.11 European gen-
eral population studies have shown considerable variation 
regarding the overall prevalence of continuous deep seda-
tion until death from 2.5% to 18.3%12–14 with one of the 
highest increase observed in the German-speaking part of 
Switzerland (from 4.7% in 2001 to 17.5% in 2014).6,15 In 
2014, every third patient admitted to hospital, palliative 
care unit or hospice died continuously deeply sedated.6 
This variability in estimates are partly due to a lack of a 
common sedation definition stemming from different pro-
cedural and conceptual sedation understandings that are a 
function of physicians’ specialties, patients’ population, 
available resources and cultural and legal backgrounds.6
In specialized palliative care, the use of sedative sub-
stances intended to induce a patient’s unconsciousness as 
an option of last resort when treating refractory symp-
toms is defined as ‘palliative sedation’.10 Palliative seda-
tion is one of the most controversial issues in end-of-life 
care, as international variation in prevalence suggests dif-
ferent sedation practices.16–18
To ensure best clinical practice for palliative sedation in 
terminally ill patients, several guidelines have been devel-
oped.19–21 In Switzerland, the first national guideline was 
released in 2005 by the Swiss Association of Palliative 
Care.22 According to this guideline, palliative sedation, 
and particularly continuous deep sedation, until death is 
indicated only when terminally ill patient’s unconscious-
ness is intended because no alternatives for palliation of 
refractory symptoms are available. Inappropriate seda-
tion occurs when induced earlier than days or hours 
before a patient’s death and medications other than ben-
zodiazepines are used, for example, opioids.10
Despite these clinical guidelines, there is no consensus 
regarding the sedation definition and practice.18,23,24 
Previous findings indicate that, in specialized palliative 
care, the induction of patient’s unconsciousness appears 
predominantly as primary intention, while outside spe-
cialized palliative care patient’s unconsciousness was 
more often taken into account as a side-effect of intensi-
fied alleviation of pain.25 Previous studies reveal that dif-
ferent sedation understandings and definitions have 
considerable consequences for how sedation is prac-
tised.26 The extent to which existing population-wide 
prevalence estimates are indicative for setting-specific 
sedation types and how these are differentiated from 
conventional symptom control remains unclear.
Therefore, we aimed to identify patient and care char-
acteristics associated with continuous deep sedation until 
death in different care settings. Furthermore, we aimed to 
investigate how decisions to intensify alleviation of pain 
and symptoms are associated with continuous deep seda-
tion until death in different care settings.
Methods
Study design
We conducted a national mortality follow-back study on a 
continuous random sample of death registrations 
between August 2013 and February 2014 in Switzerland. 
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Under conditions of strict anonymity, we sent 8954 ques-
tionnaires to certifying physicians in all three language 
regions (German, French, Italian). The last completed 
questionnaire was received on 11 June 2014. The study 
was approved by the Zurich Cantonal Ethics Board (KEK-
StV-Nr. 23/13). Written informed consent was not required 
because this study did not belong to the Human Research 
Act of the Swiss law. More details of the study methods 
including the questionnaire are given elsewhere.7,8
Questionnaire
If death was not sudden and unexpected, the case was 
considered eligible for questions regarding end-of-life 
decisions. Furthermore, to ensure that the respondents 
were actually the providers of the patient’s end-of-life 
care, the first contact between the certifying physician 
and the patient had to occur before the patient’s death. In 
such cases, physicians were asked whether they had (1) 
withheld or withdrawn a life-prolonging medical treat-
ment taking into account the possibility of hastening the 
patient’s death or explicitly intending to hasten or not to 
postpone the patient’s death; (2) intensified the allevia-
tion of pain and/or symptoms with drugs taking into 
account or partly intending hastening the patient’s death 
or (3) prescribed or administered a drug with the explicit 
intention of ending the patient’s life (physician-assisted 
death). For all patients with at least one end-of-life deci-
sion, physicians were asked to estimate how much their 
action had shortened life, from not life shortening up to 
more than 6 months of estimated shortened survival 
time.
Furthermore, we asked physicians if their patient 
received drugs, such as benzodiazepines and/or other 
sedative substances, to keep him or her in deep sedation 
or coma until death. To answer these questionnaires, phy-
sicians could access medical files.
Patient’s demographics (age, sex, marital status) were 
available from death certificates and clinical characteris-
tics (place of death, cause of death) from the 
questionnaire.
For the purpose of this study, we focused on intensified 
alleviation of pain and symptom treatments as particu-
larly these can overlap with continuous deep sedation 
until death. For questionnaire, see Supplemental Material.
Analysis
We weighted all data to adjust for region-, age- and sex-
related differences in response rates. Stratified binary 
logistic regression was used to calculate odds ratios (ORs), 
95% confidence intervals (CIs) and p-values of potential 
determinants of the administration of continuous deep 
sedation until death (yes/no) in different care settings. To 
account for missing data in covariates (range 0.2%–1.3%), 
we performed multiple imputation. We calculated post 
hoc sensitivity analyses to assess the effects of interac-
tions in order to identify significant differences between 
specific patient demographics, clinical settings and inten-
sified alleviation of symptoms. All analyses were con-
ducted using STATA IC for Macintosh (version 13.1, College 
Station, TX, USA).
Results
Study population
The sampled deaths represented 21.3% of registered 
deaths of people aged 1 year and above in the German-
speaking Switzerland, 41.1% of registered deaths in 
French-speaking regions and 62.9% of registered deaths 
in the Italian-speaking region. In total, 8963 question-
naires were mailed to the certifying physicians, of which 
5328 (59.4%) were returned until 11 June 2014. Of all cer-
tified deaths, 3678 were non-sudden and expected and 
therefore eligible for medical end-of-life decisions and 
continuous deep sedation until death.
Characteristics of patients continuously 
deeply sedated across healthcare settings
Across all healthcare settings, every fourth patient 
received sedative substances to be kept in deep sedation 
until death. Of these, the majority died in hospital 
(n = 526) or a nursing home (n = 311) and only a minority 
in specialized palliative care (n = 60) or at home (n = 80). 
Continuous deep sedation appeared to be done primarily 
together with intensified alleviation of pain and symptom 
treatments, particularly in nursing home and at home. In 
palliative care unit/hospice (31.1%) and hospital (21.3%), 
continuous deep sedation more often appeared without 
intensified alleviation of pain and symptom treatments 
compared to nursing homes (12.5%) and at home (11.2%). 
Although hastening of the patient’s death was mostly 
taken into account for intensified alleviation of pain and 
symptom treatments (82.6%), physicians rarely presumed 
these treatments to be life shortening, particularly not in 
palliative care units or hospice (94.2%). In nursing homes 
(18.8%) and at home (22.5%), physicians more often 
intensified alleviation of pain and symptom treatments 
with the explicit intention to hasten the patient’s death 
and thus more often presumed life-shortening effect.
As shown in Table 1, the distribution of patients’ demo-
graphics varied between the different care settings. In 
specialized palliative care, continuously deeply sedated 
patients were younger (71.0 years) than in other settings, 
were more often female (64.6%) and were primarily diag-
nosed with cancer (76.4%). In contrast, in nursing homes, 
sedated residents were generally older than 80 years at 
time of death (80.8%), often widowed (49.7%) and 
4 Palliative Medicine 00(0)
Table 1. Sociodemographic and clinical characteristics of 3678 non-sudden deaths and 977 patients continuously deeply sedated 
until death all over Switzerland 2013/2014.
Non-sudden 
deaths, N = 3678
Patients continuously deeply sedated until death
 PCU & hospice 
(Ntot = 172, 
nCDS = 60)
Hospital 
(Ntot = 1497, 
nCDS = 526)
Nursing home 
(Ntot = 1539, 
nCDS = 311)
At home 
(Ntot = 464, 
nCDS = 80)
 % (n) % (n) % (n) % (n) % (n)
Age in years, mean (SD) 78.3 (11.9) 71.0 (12.3) 74.1 (12.3) 84.1 (8.2) 75.5 (12.9)
 1–64 11.6 (443) 28.5 (17) 23.2 (127) 3.4 (11) 20.7 (17)
 65–79 24.8 (943) 42.2 (26) 38.0 (200) 15.8 (51) 29.4 (24)
 80+ 63.6 (2292) 29.3 (17) 38.8 (199) 80.8 (249) 49.9 (39)
Sex
 Female 54.7 (1963) 64.6 (38) 44.9 (233) 63.3 (194) 42.6 (34)
 Male 45.3 (1715) 35.4 (22) 55.1 (293) 36.7 (117) 57.4 (46)
Marital status
 Single 10.3 (378) 8.8 (5) 11.7 (61) 9.3 (29) 7.3 (6)
 Married 38.8 (1441) 44.3 (27) 53.4 (283) 31.3 (98) 58.7 (47)
 Widowed 41.3 (1492) 27.3 (16) 25.3 (129) 49.7 (153) 29.0 (23)
 Divorced 9.6 (363) 17.9 (11) 9.6 (53) 9.7 (31) 5.1 (4)
 Other 0.02 (4) 1.8 (1) 0 (0) 0 (0) 0 (0)
Cause of death
 Cardiovascular disease 25.3 (904) 3.1 (2) 24.1 (126) 28.7 (88) 11.5 (9)
 Cancer 29.6 (1152) 76.4 (46) 37.9 (200) 18.5 (58) 69.5 (56)
 Pulmonary disease 10.6 (401) 6.8 (4) 11.6 (61) 13.6 (42) 5.0 (4)
 Neurovascular diseasesa 18.0 (642) 10.2 (6) 8.9 (46) 27.5 (87) 8.9 (7)
 Other 16.5 (579) 3.6 (2) 17.5 (93) 11.8 (36) 5.2 (4)
Physicians’ experienceb
 0–2 deaths 12.8 (466) 0.0 (0) 9.6 (49) 8.6 (26) 26.2 (21)
 3–9 deaths 50.3 (1804) 14.9 (9) 39.8 (209) 51.6 (161) 57.7 (46)
 10+ 36.9 (1372) 85.1 (51) 50.6 (265) 40.8 (123) 16.1 (13)
Artificial nutrition and hydration (ANH)
 No CDS 74.6 (2701) NA NA NA NA
 CDS with ANH 7.3 (295) 13.9 (8) 46.2 (244) 10.1 (32) 13.9 (8)
 CDS without ANH 18.1 (682) 86.1 (52) 53.8 (282) 89.9 (279) 87.1 (52)
Intensified alleviation of symptoms (APS)
 No APS 37.0 (1366) 31.1 (19) 21.3 (112) 12.5 (39) 11.2 (9)
 APS only 11.7 (449) 11.8 (7) 10.0 (54) 8.1 (25) 12.3 (10)
APS combined with NTD 49.6 (1796) 50.4 (30) 66.3 (347) 75.8 (236) 70.2 (56)
APS combined with PAD 1.7 (67) 6.7 (4) 2.4 (13) 3.6 (11) 6.3 (5)
Physicians’ intention of APSb,c
 Hastening of death taken into account 82.6 (1910) 87.9 (85) 84.7 (848) 81.2 (782) 77.5 (193)
 Hastening of death intended 17.4 (402) 12.1 (11) 15.3 (153) 18.8 (186) 22.5 (52)
Estimated life shortening of APSb,d
 Not life shortening 64.3 (578) 94.2 (14) 58.4 (89) 48.2 (35) 42.9 (10)
 Less than 24 h 14.2 (133) 5.8 (1) 16.4 (24) 22.2 (17) 28.2 (7)
 Up to 1 week 16.3 (149) 0 (0) 20.0 (33) 20.8 (16) 25.0 (6)
 Up to 1 month 3.6 (31) 0 (0) 4.7 (6) 7.2 (5) 0 (0)
 Up to 6 months 1.2 (11) 0 (0) 0.5 (1) 0 (0) 3.8 (1)
 More than 6 months 0.04 (3) 0 (0) 0 (0) 1.5 (1) 0 (0)
PCU: palliative care unit; SD: standard deviation; CVD: cardiovascular disease; CDS: continuous deep sedation until death; APS: intensified alleviation 
of symptoms; NTD: forgoing life-prolonging treatment decision; PAD: physician-assisted death; NA: not available.
Figures are column percentages and numbers. Percentages are weighted according to the age at 2014. N values are unweighted.
aDiseases of the nervous system including stroke and dementia.
bMissing data: 6 place of death; 36 physicians’ experience; 123 continuous deep sedation until death; 193 APS intention and 270 estimated life 
shortening of APS.
c100% = all cases with an intensified alleviation of symptom decision.
d100% = all cases with an intensified alleviation of symptom decision and without an intended forgoing treatment decision.
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suffering of cardio- (28.7%) or neurovascular disease 
(27.5%). In hospital, sedation was less often provided to 
women, older patients and patients suffering from cancer. 
At home, continuous deep sedation was also provided 
more often to men.
Multivariate analyses
Multivariate analyses revealed that overall the administra-
tion of continuous deep sedation until death was more likely 
for patients aged less than 65 years (OR range: 1.53–2.34) 
and patients with intensified alleviation of pain and symp-
tom treatments (OR range: 1.90–10.27; Figure 1). In hospital, 
continuous deep sedation until death was significantly less 
likely for cancer patients (OR: 0.7, 95% CI: 0.5–1.0, p = 0.022), 
but more likely the younger patients were (65–79 years – OR: 
1.7, 95% CI: 1.0–2.2, p < 0.001; <65 years – OR: 2.3, 95% CI: 
1.7–3.2, p < 0.001) and the more experience a physician had 
with dying people (OR: 1.8, 95% CI: 1.2–2.7, p = 0.004). In 
nursing homes, deep sedation was more likely for patients 
who were married (OR: 1.8, 95% CI: 1.3–2.5, p = 0.001) and 
the more experience a physician had with dying people (OR: 
1.6, 95% CI: 1.0–2.7, p = 0.054). For details see Supplemental 
Material.
Discussion
Our study showed that the administration of sedative 
substances to keep a patient in deep sedation until death 
varied between healthcare settings. Across all care set-
tings, continuous deep sedation until death appeared to 
be more often applied for patients aged younger than 
65 years and as part of or after intensified alleviation of 
pain and symptoms. In hospital, sedation was less likely 
for patients suffering from cancer, but more likely the 
more experience a physician had with dying people. In 
nursing homes, sedation was more likely for people who 
were married and more likely the more experience a phy-
sician had with dying people.
The high prevalence of medical end-of-life decisions 
among sedated patients is consistent with previous find-
ings from German-speaking Switzerland as well as inter-
nationally increasing trends of intensified alleviation of 
pain treatments and increasing prescribing rates for pain 
medication.1,6,15 Findings from the Netherlands revealed 
that the use of opioids at admission to a specialized pallia-
tive care setting increased the probability of receiving 
continuous deep sedation.27 This indicates that patients 
who receive continuous deep sedation until death have 
significantly more pain problems compared to patients 
not receiving sedation.28 However, the extent to which a 
patient’s pain was refractory and, therefore, represented 
an indication for continuous deep sedation remains under 
question. Today it is not clear what ‘unbearable suffering’ 
means and when a symptom is considered refractory, par-
ticularly in case of existential suffering.29–31
The observation that pain was associated with the use 
of continuous deep sedation furthermore might explain 
Figure 1. Association of continuous deep sedation until death with patients’ socio-demographics, physicians’ experience and 
intensified alleviation of symptoms in Swiss clinical practice 2013.
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the age differences we found. Although older patients 
seem more likely to experience unbearable pain symp-
toms, previous studies have shown that younger hospital-
ized patients are more likely to report pain and more likely 
to receive pain medication.5 These findings are in line with 
the UK,32 Italian,33 Belgian34 and Dutch studies,27,35 point-
ing out a higher probability of receiving continuous deep 
sedation until death when aged younger, diagnosed with 
cancer and dying in hospital.
The age difference might further be due to selected 
patient populations. While cancer patients were often 
younger and more prevalent among continuously deeply 
sedated patients,24 pain in older people and people with 
dementia is assessed less often and therefore underesti-
mated.5,36 The high prevalence of patients suffering of 
dementia in nursing homes highlights the significance of 
having a spouse in this setting, on top of the age effect. 
This could partly explain why older people in hospitals 
and those who do not have a spouse to advocate for them 
in nursing homes are less likely to receive continuous 
deep sedation.
In specialized palliative care and hospice, continuous 
deep sedation was less often reported to be combined 
with intensified alleviation of symptom treatments. 
Recent findings from Switzerland revealed that, outside 
specialized palliative care, healthcare professionals some-
times used opioids as a sole agent to either induce con-
tinuous deep sedation intentionally or to take sedation 
into account as a side-effect of increasing analgesics.25 
There is evidence that the more the palliative care experi-
ence healthcare professionals have, the more likely they 
differentiate continuous deep sedation from possibly life-
shortening end-of-life decisions. In turn, less experienced 
healthcare professionals were more often ambivalent 
towards continuous deep sedation and thus more likely to 
consider it as possibly life shortening.37–39
The variation in sedation practice is not only related to 
professionals’ palliative care experience but also to differ-
ent resources provided by the clinical setting.40 According 
to clinical guidelines, continuous deep sedation until 
death requires a multidisciplinary decision-making pro-
cess with the option to call in palliative care experts, con-
tinuous administration of benzodiazepines and regular 
patient’s monitoring.10,20 But findings from Belgium indi-
cate that the provision of multidisciplinary exchange, con-
stant patient monitoring, intravenous infusions and access 
to sedative substances differ between healthcare set-
tings.18 Particularly, healthcare professionals working out-
side specialized palliative care have limited resources.
Our results serve as a starting point for developing a 
consensus on different types of sedation practices and its 
association with increased analgesia. However, some limi-
tations need to be addressed in future studies. This study 
presented results based on retrospective self-reported 
sedation practices that are labelled as such by the 
attending physicians. Although we limited the time 
between a patient’s death, death registration and sending 
the questionnaire to the attending physicians to a mini-
mum, some recall bias cannot be ruled out. Furthermore, 
our results outline potential for sedation under- or overes-
timation. Thus, it is unclear to which extent different seda-
tion incidence rates suggest different sedation practices 
and how they are differentiated from conventional symp-
tom control. Our results highlight the strong association 
between continuous deep sedation until death and intensi-
fied alleviation of pain and symptom treatments. However, 
our data provide no conclusion about the extent to which 
sedation was used for symptom management. Future stud-
ies should complement the self-reported data with medical 
records and data from patients’ file providing information 
on specific drugs used, their dosage, the time of adminis-
tration, as well as previously attempted treatments.
Implications
Our results illustrate that continuous deep sedation until 
death is strongly associated with intensified alleviation of 
pain and symptom treatments. To bridge the gap between 
current guidelines and everyday clinical practice, more 
attention should be paid to the management of refractory 
symptoms.41 Thus, sedation guidelines should also target 
the administration of opioids in terminally ill patients. In 
order to achieve consensus about good clinical end-of-life 
care, experiences need to be shared across healthcare 
settings. Therefore, multidisciplinary collaboration and 
education in symptom management should be improved. 
To increase a patient’s quality of life, the early recognition 
of patients who could benefit from continuous deep seda-
tion until death and thus advance care planning is 
required.42 This would allow future studies to monitor eli-
gible patients before continuous deep sedation until 
death is induced.
Furthermore, healthcare settings should be provided 
with professional and financial support to allow profes-
sionals to call in experts for decision-making and to pro-
vide constant patient monitoring needed for continuous 
deep sedation until death.
Conclusion
The healthcare setting plays a key role in understanding 
the variation in the administration of sedative substances, 
to keep a patient in deep sedation or coma until death. 
Across all settings, continuous deep sedation until death 
appears to be provided primarily as part of or after inten-
sified alleviation of pain and symptoms. But the ability to 
speak up for oneself and report pain seems less likely with 
patients’ increasing age and cognitive impairment. 
Therefore, unmarried patients in nursing homes and 
patients aged ⩾80 in hospitals might be at higher risk of 
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not receiving continuous deep sedation until death when 
warranted.
Acknowledgements
We thank the Swiss Federal Statistical Office for having sam-
pled deaths for our study and the Swiss Academy of Medical 
Sciences (SAMS) for ensuring anonymity of questionnaires. We 
particularly thank all the physicians who participated in the 
study and filled in the end-of-life decision questionnaires. S.Z. 
designed the research question, performed the data analysis 
and drafted the first and final versions of the manuscript. M.S., 
M.B., G.B. and M.A.P. substantially contributed to the design of 
the study, carrying out the survey and the interpretation of the 
results and critically revised the manuscript. M.A.P. gave final 
approval to submission. All authors read and approved the final 
manuscript.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of inter-
est with respect to the research, authorship and/or publication 
of this article: the authors declare that there is no conflict of 
interest.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship and/or publication of this 
article: This work and one of the coauthors (S.Z.) were sup-
ported by the Swiss National Science Foundation (research 
grant 406740-139309, National Research Programme 67 ‘End 
of Life’), the Palliative Care Research funding programme of 
the Swiss Academy of Medical Sciences, the Gottfried and 
Julia Bangerter-Rhyner Foundation and the Stanley Thomas 
Johnson Foundation (grant PC 03/16). The funding 
bodies had no role in study design and conduction, data 
collection, analysis and interpretation and in writing of the 
manuscript.
Supplemental material
Supplemental material for this article is available online.
ORCID iD
Sarah Ziegler  https://orcid.org/0000-0002-9907-5787
References
 1. Wertli MM, Reich O, Signorell A, et al. Changes over time 
in prescription practices of pain medications in Switzerland 
between 2006 and 2013: an analysis of insurance claims. 
BMC Health Serv Res 2017; 17(1): 167–111.
 2. Larsson C, Hansson EE, Sundquist K, et al. Chronic pain in 
older adults: prevalence, incidence, and risk factors. Scand 
J Rheumatol 2017; 46(4): 317–325.
 3. van Hecke O, Torrance N and Smith BH. Chronic pain epi-
demiology and its clinical relevance. Br J Anaesth 2013; 
111(1): 13–18.
 4. Breivik H, Cherny NI, Collett B, et al. Cancer-related pain: 
a pan-European survey of prevalence, treatment, and 
patient attitudes. Ann Oncol 2009; 20(8): 1420–1433.
 5. Kim Y-S, Park J-M, Moon Y-S, et al. Assessment of pain 
in the elderly: a literature review. Natl Med J India 2017; 
30(4): 203.
 6. Ziegler S, Schmid M, Bopp M, et al. Continuous deep seda-
tion until death – a Swiss death certificate study. J Gen 
Intern Med 2018; 33: 1052–1059.
 7. Schmid M, Zellweger U, Bosshard G, et al. Medical end-
of-life decisions in Switzerland 2001 and 2013 : who is 
involved and how does the decision-making capacity of the 
patient impact? Swiss Med Wkly 2016; 146: w14307.
 8. Hurst SA, Zellweger U, Bosshard G, et al. Medical end-of-
life practices in Swiss cultural regions: a death certificate 
study. BMC Med 2018; 16(1): 54–58.
 9. Cherny NI. ESMO Clinical Practice Guidelines for the man-
agement of refractory symptoms at the end of life and the 
use of palliative sedation. Ann Oncol 2014; 25(Suppl. 3): 
iii143–iii152.
 10. Cherny NI and Radbruch L. European Association for 
Palliative Care (EAPC) recommended framework for the 
use of sedation in palliative care. Palliat Med 2009; 23(7): 
581–593.
 11. Swart SJ, van der Heide A, van Zuylen L, et al. Considerations 
of physicians about the depth of palliative sedation at the 
end of life. CMAJ 2012; 184(7): E360–E366.
 12. Miccinesi G, Rietjens JAC, Deliens L, et al. Continuous deep 
sedation: physicians’ experiences in six European coun-
tries. J Pain Symptom Manage 2006; 31(2): 122–129.
 13. Robijn L, Cohen J, Rietjens JAC, et al. Trends in continuous 
deep sedation until death between 2007 and 2013: a repeated 
nationwide survey. PLoS ONE 2016; 11(6): e0158188.
 14. Vissers KC and Hasselaar JG. Continuous deep sedation 
until death in Belgium: a nationwide survey. Arch Intern 
Med 2010; 170(5): 494–495.
 15. Bosshard G, Zellweger U, Bopp M, et al. Medical end-of-life 
practices in Switzerland: a comparison of 2001 and 2013. 
JAMA Intern Med 2016; 176(4): 555–556.
 16. Papavasiliou EE, Payne S and Brearley S. Current debates 
on end-of-life sedation: an international expert elicitation 
study. Support Care Cancer 2014; 22(8): 2141–2149.
 17. Rietjens JAC, van Delden JJ and van der Heide A. Palliative 
sedation: the end of heated debate. Palliat Med. Epub ahead 
of print 1 March 2018. DOI: 10.1177/0269216318762708.
 18. Papavasiliou EE, Chambaere K, Deliens L, et al. Physician-
reported practices on continuous deep sedation until 
death: a descriptive and comparative study. Palliat Med 
2014; 28(6): 491–500.
 19. Abarshi E, Rietjens JAC, Robijn L, et al. International varia-
tions in clinical practice guidelines for palliative sedation: 
a systematic review. BMJ Support Palliat Care 2017; 7(3): 
223–229.
 20. Schildmann E and Schildmann J. Palliative sedation therapy: 
a systematic review and comparative appraisal of available 
guidance on ethical and communication aspects of indica-
tion and decision-making. Onkologie 2013; 36: 199–200.
 21. Gurschick L, Mayer DK and Hanson LC. Palliative sedation: 
an analysis of international guidelines and position state-
ments. Am J Hosp Palliat Care 2015; 32(6): 660–671.
 22. palliative ch. BIGORIO 2005 Empfehlungen « Palliative 
Sedation » Konsens einer Expertengruppe von palliative ch, 
https://www.palliative.ch (2005, accessed 23 June 2015).
8 Palliative Medicine 00(0)
 23. Willems DL. The apparent gap between guidelines on pal-
liative sedation and everyday practice. Commentary on: 
general practitioners’ report on continuous deep sedation 
until death for patients dying at home: a descriptive study 
from Belgium. Eur J Gen Pract 2011; 17: 3–4.
 24. Schildmann E, Pornbacher S, Kalies H, et al. ‘Palliative seda-
tion’? A retrospective cohort study on the use and labelling 
of continuously administered sedatives on a palliative care 
unit. Palliat Med 2018; 32: 1189–1197.
 25. Ziegler S, Schmid M, Bopp M, et al. Continuous deep seda-
tion until death in patients admitted to palliative care spe-
cialists and internists: a focus group study on conceptual 
understanding and administration in German-speaking 
Switzerland. Swiss Med Wkly 2018; 148: w14657.
 26. Raus K and Sterckx S. How defining clinical practices may 
influence their evaluation: the case of continuous sedation 
at the end of life. J Eval Clin Pract 2016; 22(3): 425–432.
 27. Van Deijck RH, Hasselaar JG, Verhagen SC, et al. Patient-
related determinants of the administration of continuous 
palliative sedation in hospices and palliative care units: 
a prospective, multicenter, observational study. J Pain 
Symptom Manage 2016; 51(5): 882–889.
 28. Oosten AW, Oldenmenger WH, van Zuylen C, et al. Higher 
doses of opioids in patients who need palliative sedation 
prior to death: cause or consequence? Eur J Cancer 2011; 
47: 2341–2346.
 29. Bozzaro C. The concept of suffering in medicine: an investi-
gation using the example of deep palliative sedation at the 
end of life. Ethik Der Medizin 2015; 27: 93–106.
 30. Bozzaro C and Schildmann J. ‘Suffering’ in palliative sedation: 
conceptual analysis and implications for decision-making in 
clinical practice. J Pain Symptom Manage 2018; 56: 288–294.
 31. Voeuk A, Nekolaichuk C, Fainsinger R, et al. Continuous 
palliative sedation for existential distress? A survey of 
Canadian palliative care physicians’ views. J Palliat Care 
2017; 32(1): 26–33.
 32. Seale C. Continuous deep sedation in medical practice: a 
descriptive study. J Pain Symptom Manage 2010; 39(1): 
44–53.
 33. Miccinesi G, Caraceni A, Raho JA, et al. Careful monitor-
ing of the use of sedative drugs at the end of life: the 
role of epidemiology. Minerva Anestesiol 2015; 81(9): 
968–979.
 34. Chambaere K, Bilsen J, Cohen J, et al. Continuous deep 
sedation until death in different care settings in Belgium. 
Palliat Med 2010; 24: S16.
 35. Robijn L, Chambaere K, Raus K, et al. Reasons for continu-
ous sedation until death in cancer patients: a qualitative 
interview study. Eur J Cancer Care (Engl). Epub ahead of 
print 29 October 2015. DOI: 10.1111/ecc.12405.
 36. Zwakhalen SMG, Hamers JPH, Abu-Saad HH, et al. Pain 
in elderly people with severe dementia: a systematic 
review of behavioural pain assessment tools. BMC Geriatr 
2006; 6: 3.
 37. Foley R-A, Johnston WS, Bernard M, et al. Attitudes regard-
ing palliative sedation and death hastening among Swiss 
physicians: a contextually sensitive approach. Death Stud 
2015; 39(8): 473–482.
 38. Inghelbrecht E, Bilsen J, Mortier F, et al. Nurses’ attitudes 
towards end-of-life decisions in medical practice: a nation-
wide study in Flanders, Belgium. Palliat Med 2009; 23(7): 
649–658.
 39. Inghelbrecht E, Bilsen J, Mortier F, et al. Continuous deep 
sedation until death in Belgium: a survey among nurses. J 
Pain Symptom Manage 2011; 41(5): 870–879.
 40. Putman MS, Yoon JD, Rasinski KA, et al. Intentional seda-
tion to unconsciousness at the end of life: findings from a 
national physician survey. J Pain Symptom Manage 2013; 
46(3): 326–334.
 41. Scott JF. Sedation at the end-of-life: an interdiscipli-
nary approach. In: Taboada P (ed.) Sedation at the 
end-of-life an interdisciplinary approach, vol. 116. 
Dordrecht: Springer Science + Business Media, 2015, pp. 
143–159.
 42. Vanbutsele G, Pardon K, van Belle S, et al. Effect of early 
and systematic integration of palliative care in patients 
with advanced cancer: a randomised controlled trial. 
Lancet Oncol 2018; 19: 394–404.
